Leriglitazone

Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases.

Society and culture

Legal status

In January 2024, the European [Medicines Agency] recommended the refusal of the marketing authorization for leriglitazone requested by Minoryx Therapeutics S.L. In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone. Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy.